My MSAA Community – Recognizing Five Years of Support from the Multiple Sclerosis Association of America

The Multiple Sclerosis Association of America’s (MSAA) free online support forum, My MSAA Community, has been a continued source of support, encouragement, and hope for members of the multiple sclerosis (MS) community since its creation in 2016. Powered by HealthUnlocked, My MSAA Community offers people with multiple sclerosis, care partners, friends, and family members a […]

Read News Article

What’s New in MS Research – May 2021

Reviewed by MSAA Chief Medical Officer Barry A. Hendin, MD In this Article Do you and your neurologist attach the same importance to various DMT benefits and risks? Characteristics and clinical outcomes of underserved minority patients with multiple sclerosis MRI findings yield clues to likelihood of MS worsening in pediatric patients Young and stressed over […]

Read News Article

Join the Multiple Sclerosis Association of America for the First-Ever Virtual Improving Lives Benefit in Support of the MS Community

For six years, the Multiple Sclerosis Association of America (MSAA) has been honored to host our annual Improving Lives Benefit in-person, raising funds for the MS community. Now, MSAA is excited to bring our community “Together at Home” for our first-ever virtual Improving Lives Benefit, showcasing more than 50 years of hope, impact, and support […]

Read News Article

What’s New in MS Research: March 2021

The first quarter of 2021 has been marked by welcome news on the medical front, and those hopeful developments aren’t limited to the increasing number of COVID-19 vaccinations being given across the country. Significant strides in treating and understanding MS also have been made in these early months of the year, as detailed in this edition of “What’s New in MS Research.”

Read News Article

FDA Approves Ponvory for the Treatment of Relapsing Forms of MS

Updated: March 25, 2021 to include patient assistance resource information Reviewed by MSAA Chief Medical Officer Barry A. Hendin, MD The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the United States Food and Drug Administration (FDA) approved Ponvory™ (ponesimod) for the treatment of relapsing forms of multiple sclerosis (MS) in adults – including […]

Read News Article

The Multiple Sclerosis Association of America (MSAA) Focuses on Improving Mental Health and Wellness in Honor of MS Awareness Month

The Multiple Sclerosis Association of America (MSAA) recognizes March as Multiple Sclerosis (MS) Awareness Month. MSAA is proud to announce the 2021 awareness campaign theme on Improving Mental Health and Wellness, with specific programs addressing Purpose in Life, depression and anxiety in MS, care partnering, and wellness strategies to improve symptom management and overall quality […]

Read News Article

What’s New in MS Research: January 2021

The expression, “Here’s hoping this year is better than the last” has particular poignancy as we transition into 2021. Happily, much of the recent news regarding multiple sclerosis (MS) provides cause for considerable hope, as reflected in the study results and other reports featured in this month’s iteration of “What’s New in MS Research.”

Read News Article

Impact Education, LLC and MSAA Release New Whitepaper on Payer Considerations for Providing Support to People With MS and Their Care Partners

BLUE BELL, Pa.–(BUSINESS WIRE)–Impact Education, LLC (IMPACT) and the Multiple Sclerosis Association of America (MSAA) announce the release of a new whitepaper based on key findings from a series of dynamic roundtable discussions between payers and multiple sclerosis (MS) healthcare providers. MS affects about 1,000,000 people in the United States and while quality care is […]

Read News Article

What’s New in MS Research: November 2020

While we all know “MS” stands for “multiple sclerosis,” with so much exciting research reported in this edition of “What’s New in MS Research,” we can almost imagine that “MS” could also refer to the quest for “multiple solutions” in MS. Although a great deal of the research looks to further understand the biology, easing the symptoms, and slowing or stopping the physical damage of MS, the studies and other information presented here are very encouraging – and they are only a small sample of the vast array of research under way around the world.

Read News Article

What’s New in MS Research: September 2020

This edition of MSAA’s “What’s New in MS Research” article features highlights from the annual meetings of the American Academy of Neurology (AAN) and the Consortium of MS Centers (CMSC). Because of the ongoing COVID-19 pandemic, both of these meetings were held virtually. While not all of the reports are positive, the good far outweighs the rest, and encompasses not only promising research advances in MS, but also a potential role for a long-established DMT in treating COVID-19.

Read News Article